- Home
- ROIV vs TIGO Comparison
ROIV vs TIGO Comparison
Compare ROIV & TIGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- TIGO
- Stock Information
- Founded
- ROIV 2014
- TIGO 1990
- Country
- ROIV United Kingdom
- TIGO Luxembourg
- Employees
- ROIV N/A
- TIGO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- TIGO Telecommunications Equipment
- Sector
- ROIV Health Care
- TIGO Telecommunications
- Exchange
- ROIV Nasdaq
- TIGO Nasdaq
- Market Cap
- ROIV 8.6B
- TIGO 8.1B
- IPO Year
- ROIV N/A
- TIGO 1994
- Fundamental
- Price
- ROIV $16.17
- TIGO $48.15
- Analyst Decision
- ROIV Strong Buy
- TIGO Hold
- Analyst Count
- ROIV 8
- TIGO 5
- Target Price
- ROIV $19.94
- TIGO $43.62
- AVG Volume (30 Days)
- ROIV 9.5M
- TIGO 1.0M
- Earning Date
- ROIV 11-11-2025
- TIGO 11-06-2025
- Dividend Yield
- ROIV N/A
- TIGO 6.23%
- EPS Growth
- ROIV N/A
- TIGO 792.62
- EPS
- ROIV N/A
- TIGO 5.57
- Revenue
- ROIV $23,233,000.00
- TIGO $5,605,000,000.00
- Revenue This Year
- ROIV N/A
- TIGO N/A
- Revenue Next Year
- ROIV $248.22
- TIGO $8.68
- P/E Ratio
- ROIV N/A
- TIGO $8.62
- Revenue Growth
- ROIV N/A
- TIGO N/A
- 52 Week Low
- ROIV $8.73
- TIGO $23.61
- 52 Week High
- ROIV $16.19
- TIGO $50.78
- Technical
- Relative Strength Index (RSI)
- ROIV 80.34
- TIGO 53.60
- Support Level
- ROIV $14.86
- TIGO $46.67
- Resistance Level
- ROIV $16.15
- TIGO $48.74
- Average True Range (ATR)
- ROIV 0.43
- TIGO 1.35
- MACD
- ROIV 0.06
- TIGO -0.26
- Stochastic Oscillator
- ROIV 99.12
- TIGO 40.44
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About TIGO Millicom International Cellular S.A.
Millicom offers wireless and fixed-line telecom services primarily in smaller, less developed countries in Latin America. Countries served include Bolivia (100% owned), Nicaragua (100%), Panama (100%), El Salvador (100%), Guatemala (100%), Paraguay (100%), Colombia (50%), and Honduras (67% but not controlled or consolidated in the firm's financial statements). The firm's wireless networks cover about 120 million people, serving 42 million customers. Its fixed-line networks reach 14 million homes, serving about 4 million broadband customers. Increasingly, Millicom offers converged packages that include broadband with wireless services. The firm has agreed to acquire Telefonica's operations in Ecuador and Uruguay.